OverviewThe global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
Final 2025 global cohort onboarding, with applications now open for 2026WILMINGTON, Mass.--(BUSINESS WIRE)--$CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ...
Charles River Laboratories International Inc. has announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback